18-Feb-2020 | Zion Market Research
Zion Market Research has published a new report titled “Intravenous Iron Drugs Market by Product (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, and Others) and Application (Cancer, Inflammatory Bowel Disease, Chronic Kidney Disease, and Other Diseases): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025” According to the report, global demand for intravenous iron drugs market was valued at approximately USD 1,699.5 Million in 2018, and is expected to generate revenue of around USD 2,851.7 Million by end of 2025, growing at a CAGR of around 7.8% between 2019 and 2025.
Browse the full “Intravenous Iron Drugs Market by Product (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, and Others) and Application (Cancer, Inflammatory Bowel Disease, Chronic Kidney Disease, and Other Diseases): Global Industry Perspective, Comprehensive Analysis and Forecast, 2019 – 2025.” Report at https://www.zionmarketresearch.com/report/intravenous-iron-drugs-market
Iron is one of the many minerals that exist within the human body. Iron is a constituent of hemoglobin that makes it a significant mineral. The shortage of iron in the human body leads to incapability in manufacturing hemoglobin, which may lead to anemia occurrence. Elderly people and women are at a bigger risk of acquiring iron-deficiency anemia. Oral iron supplementation is supplied to treat iron-deficiency. Nevertheless, oral iron supplementation cannot be administered to some individuals. People affected with inflammatory bowel disease, patients undergoing kidney dialysis, iron-deficiency anemia patients undergoing heavy blood loss surgery, and celiac disease patients among others are given intravenous iron drugs.
Factors such as increasing incidence of chronic renal disease, increasing geriatric population, growing number of dialysis patients, increasing cases of iron-deficiency anemia, increasing number of surgeries, and growing investment in research and development by major manufacturers will act as major driving factors in the growth of global intravenous iron drugs market. Development of novel products, growing need for prevention of anemia in pregnant women, and growing use in gynecology will act as an opportunity for the market players in the intravenous iron drugs market. Nonetheless, some side-effects associated with intravenous iron drugs, stringent regulations, high cost as compared to oral supplements, and complex approval process will restrict the growth of global intravenous iron drugs market.
The global intravenous iron drugs market has been split into product, application. Based on product, intravenous iron drugs market has been segmented into ferric carboxymaltose, iron sucrose, iron dextran, and others. The ferric carboxymaltose segment accounted for the highest market share in 2018 due to growing applications of ferric carboxymaltose in drug discovery and reduction in costs. The application segment has been segmented into cancer, inflammatory bowel disease, chronic kidney disease, and other diseases. The chronic kidney disease segment accounted for the highest market share in 2018 due to growing prevalence, increasing geriatric population, and growing inclination towards sedentary lifestyle.
Regionally, the intravenous iron drugs market is segmented into North America, Latin America, Asia Pacific, Europe, and the Middle East & Africa. North America will be the leading region during the forecast period. High investment in research and development of intravenous iron drugs, applications in the field of cancer research, and growing adoption of intravenous iron drugs will boost the market growth in this region. Europe will be the second largest market. The major reasons are advantageous reimbursement scenario, high diabetes prevalence, and presence of key market players. Asia Pacific will propagate at speedy rate over the forecast period due to launch of novel products, high prevalence of chronic renal ailments, and growing investment by government in biopharmaceutical industry. Latin America market will develop at a significant rate during the forecast period. The Africa and Middle Eastern region is likely to exhibit perceptible progression in the projected time-frame.
The report also includes detailed profiles of key players such as Daiichi Sankyo Company, Ltd., Allergan, Inc., Sanofi, Rockwell Medical Technologies, Inc., Fresenius Medical Care AG & Co., AMAG Pharmaceuticals. Inc., Pharmacosmos A/S, Vifor Pharma Management Ltd., American Regent. Inc., and Shield Therapeutics Plc among others.
This report segments the Global Intravenous Iron Drugs Market as follows:
Global Intravenous Iron Drugs Market: By Product
Global Intravenous Iron Drugs Market: By Application
Global Intravenous Iron Drugs Market: By Region
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651